Experimental spore therapy slashes C. difficile reinfection risk
Most patients had a sustained clinical response 'out to about six months', researchers say
An experimental three-day therapy that involves introducing Firmicutes spores into the gut may reduce the risk of Clostridium difficile reinfection by nearly 70%, a phase III trial shows.
The treatment, known as SER-109, appeared to be more effective in patients under 65, which the US researchers say is “clinically important” given their increased risk of recurrent disease and hospital readmission.
